



# idiS

## 2023 ANNUAL REPORT Memoria anual



A large, abstract network graph is visible in the background, composed of numerous light blue and grey circular nodes connected by thin blue lines.

## EDITION AND PRODUCTION

Scientific-Technical Coordination  
of the Health Research Institute  
of Santiago de Compostela

**José Ramón Castro Ruibal**  
Technical Management

**Yolanda Liste Martínez**  
Technical Management

**Iria Louzao Pernas**  
Technical Management

## APPROVAL

*Direction Board of the Institute  
at the meeting on 16 May, 2024.*





## Mª Luz Couce Pico

Directora Científica  
*Scientific Director*

**“Grazas a todos vós batemos récords,  
de novo, nos nosos indicadores:  
captáronse más de 50 M€ en  
actividades de investigación,...”**

Compráçeme presentarvos a memoria científica do IDIS un ano máis para compartir os avances obtidos en 2023 e recoñecer o gran traballo realizado por todos os profesionais. Grazas a todos vós batemos récords, de novo, nos nosos indicadores: captáronse máis de 50 M€ en actividades de investigación, dos cales, máis do 60% foron obtidos a través de convocatorias competitivas. Ademais a nosa captación internacional consolídase coa participación en 21 novos proxectos europeos, e a nosa producción científica segue estando a un extraordinario nivel cualitativo e cuantitativo, xa que o 45% dos nosos traballos científicos lévanse a cabo con grupos internacionais.

Non podemos esquecer que temos unha responsabilidade na captación e retención de talento, e debemos proporcionar unha actividade formativa ás novas xeracións. Neste sentido, levamos a cabo unha intensa labor mediante a organización de cursos, seminarios, congresos e outras actividades orientadas ó coñecemento. Ademais, debemos ter moi presente a importancia de difundir a ciencia á sociedade, tendo xerado un significativo número de actuacións en materia de divulgación científica.

En 2023 establecemos un novo rumbo coa elaboración e aprobación do plan estratéxico para os próximos 5 anos, mediante o cal se pretende dar un impulso á actividade que desenvolvemos, potenciando o progreso de terapias avanzadas, favorecendo a nosa posición en estruturas cooperativas a nivel nacional e internacional, optimizando os nosos recursos e procesos de xestión e estimulando unha cultura innovadora que facilite a traslación de resultados a nosa sociedade. Estes son algúns dos ámbitos nos que se centra o plan, que servirá de ferramenta para incrementar a nosa competitividade e afrontar os retos futuros con solvencia.

Para continuar nesta senda precisamos seguir tendo masa crítica, recursos e espazo. Os recursos son crecientes, a masa crítica tamén o é, pero precisamos máis espazo, novas instalacións, e iso preocúpanos cada vez máis. Agardamos que pronto o teñamos dispoñible para poder seguir desenvolvendo a investigación dunha forma óptima. Para os próximos anos esperámos desafíos ándia maiores, pero confiamos en que, con determinación e colaboración, podemos superar calquera obstáculo que



se presente no noso camiño. Seguiremos traballando para desenvolver novas ferramentas innovadoras e promover políticas que melloren a saúde das persoas.

Gustaríame lembrar, que froito da nosa labor científica, o pasado ano ASOMEGA nos concedeu o distintivo de ouro. Este recoñecemento, xunto cos resultados tan positivos que presentamos servirános de impulso para seguir realizando unha ciencia excelente e tendo presente a cooperación, pois somos conscientes de que o éxito nunca é dunha persoa soa, é dun equipo de profesionais que traballan con ilusión e motivación.

Estamos próximos a ter que solicitar ó ISCIII a nosa reacreditación como Instituto. Sabemos que é unha carreira de fondo e este ano tócanos o sprint final, por iso solicito o voso apoio.

Esta memoria non é máis que o relato conxunto das vosas excelentes aportacións ó noso Instituto. Moitas grazas polo entusiasmo e dedicación que lle imprimides ó voso traballo diario cun claro obxectivo: mellorar a saúde da poboación.

*I am pleased to present the IDIS scientific report for another year to share the progress made in 2023 and recognize the great work done by all professionals. Thanks to all of you we have broken records, again, in our indicators: more than €50 M have been raised for activities of research, of which, more than 60% have been obtained through competitive calls. Furthermore, our international fundraising is consolidating with the participation in 21 new European projects, and our scientific production continues to be at an extraordinary qualitative and quantitative level, since 45% of our scientific work is carried out with international groups.*

*We cannot forget that we have a responsibility in attracting and retaining talent, and we must provide training to new generations. In this sense, we have carried out intense work by organizing courses, seminars, conferences and other knowledge-oriented activities. Furthermore, we must keep in mind the importance of disseminating science to society, having generated a significant number of actions in terms of scientific dissemination to the general public.*

In 2023 we have established a new direction with the development and approval of the strategic plan for the next 5 years, through which we intend to give a boost to the activity we develop, promoting the progress of advanced therapies, favoring the positioning in cooperative structures at national and international level, optimizing our resources and management processes and stimulating an innovative culture that facilitates the transfer of results to our society. These are some of the areas on which the plan focuses, which will serve as a tool to increase our competitiveness and face future challenges with solvency.

To continue with this path we need critical mass, resources and space. The resources are increasing, the critical mass is also increasing, but we need more space, new facilities, and this concerns us more and more. We hope that we will soon have more space available so that we can continue developing the research in optimal conditions. Even greater challenges await us in the coming years, but we are confident that, with determination and collaboration, we can overcome any obstacle in our path.

We will keep working to develop new innovative tools and promote policies that improve people's health.

I would like to remember that, due to our scientific work, last year ASOMEGA awarded us the gold insignia. This recognition, together with the very positive results that we present, will serve as a boost to continue carrying out excellent science and keeping cooperation in mind, since we are aware that success never belongs to a single person, but to a team of professionals who work with enthusiasm and motivation.

We are close to applying for our reaccreditation as an Institute from the ISCIII. We know that it is a long-distance race and this year we have the final sprint, which is why I ask for your support.

This report is nothing more than the joint narrative of your excellent contributions to our Institute. Thank you very much for the enthusiasm and dedication that you bring to your daily work with a clear objective: to improve the health of the population.

# Summary



- 
01. EXECUTIVE SUMMARY 12
  02. GLOBAL ANALYSIS 16
  03. STRUCTURE 38
  04. TRAINING & DISSEMINATION 50
  05. INNOVATION AND TRANSFER 56
  06. PLATFORMS 64
  07. FUNDING 76
  08. STRATEGIC ALLIANCES 84
  09. AREAS 88
  10. BALANCE DE SITUACIÓN Y CUENTA DE RESULTADOS 102

A faint, abstract network graph serves as the background for the entire slide. It consists of numerous small, semi-transparent circular nodes of varying sizes and colors (light blue, medium blue, dark blue, grey) connected by thin, light blue lines, creating a sense of a complex system or data connections.

# EXECUTIVE SUMMARY

# 01

The Health Research Institute of Santiago de Compostela (IDIS) is a biomedical research center of marked translational character that takes advantage of the synergies of the University Clinical Hospital of Santiago de Compostela (CHUS) and the University of Santiago de Compostela (USC) to promote and encourage excellent research, scientific and technological knowledge and its subsequent transfer to the productive sector, as well as teaching and training, focused on a clear objective: to improve the people's health.





## Strategic Plan


- 1. HUMAN CAPITAL**
- 2. INSTITUTIONAL RELATIONS AND INTERNATIONALIZATION**
- 3. CLINICAL-TRANSLATIONAL RESEARCH AND INNOVATION**
- 4. SCIENTIFIC DEVELOPMENT**
- 5. MANAGEMENT AND RESOURCES**

**01.**



**52.309.190 €**

TOTAL FUNDS RAISED




120  
Projects

158  
Donations

277  
Clinical  
Studies

411  
Contracts  
and provision  
of services

81  
Staff  
contracts



1.008  
Published  
articles

10  
Granted  
patents

90  
PhD  
Theses

47  
Requested  
patents



# GLOBAL ANALYSIS

02




HEALTH RESEARCH INSTITUTE. SANTIAGO DE COMPOSTELA



## RESEARCH AREAS

7





Platforms and Methodology	Cardiovascular	Infectology, Inflammation and Vaccines
160	172	172
67 Women 93 Men	99 Women 73 Men	101 Women 71 Men
13	12	11



RESEARCH  
and TECHNICAL STAFF

**1.338**

757 Women  
581 Men


TRANSVERSAL

**35** ▲ 30 Women  
5 Men





## Number of researchers per area





105  
GROUPS

Consolidated  
418 Women  
317 Men



44  
groups

Emerging  
233 Women  
169 Men



45  
groups

Clinical Associate  
76 Women  
90 Men



16  
groups



735  
researchers



402  
researchers



166  
researchers



1.303  
RESEARCHERS

35  
TRANSVERSAL


1.338 PEOPLE



## Researchers




Research staff fully or partially funded through competitive calls and research networks.




## Number of published articles per year

The Institute has published 1.008 original scientific articles, editorials and reviews in 632 international journals indexed in the *Journal Citation Report* with a cumulative impact factor of 7.432,4 points.




## Average impact factor

The average impact factor has reached 7.4\* in 2023.




\*As of JCR 2023, the JIF only offers one decimal place, instead of the three offered until last year.

## Number of articles published in journals ranked in the first decile



The **number of articles in leading journals increases (D1)** has increased along the period 2013 - 2023. In 2023, **214 articles** were published in D1 ranked journals.

## Number of published articles per year, by journal quartile




As of 2023, those journals receiving a JIF for the first time in June 2023, they will not receive ranks, quartiles, or percentiles until the release of 2023 data in JCR 2024.

## Number of publications and % of the total in 2023


Regarding the articles authorship, we identify those publications whose main authors (first, last or corresponding author) are affiliated to an IDIS group.

**949** Originals and reviews



**469** Originals and reviews

**160** Female preferred autor (34,1%)



As of 2023, those journals receiving a JIF for the first time in June 2023, they will not receive ranks, quartiles, or percentiles until the release of 2023 data in JCR 2024.

\* Publication gender is assigned considering the corresponding author/s in the first place, then last author and finally, first autor.

## Publications in 2023

Number and % of articles published in collaboration between IDIS groups and groups of centres outside of Spain.



24,01%

**242**

Articles published in collaboration between IDIS groups.



44,94%

**453**

Articles published in collaboration between groups of centres outside of Spain.

		Q1 (%)	D1 (%)
Originals	809	440 (54.4%)	179 (22.1%)
Reviews	140	51 (36.4%)	19 (13.6%)
Editorial Material	59	42 (71.2%)	16 (27%)
<b>Total</b>	<b>1008</b>		



## Summary of the funding raised in 2023

CONCEPT	NUMBER	AMOUNT
Projects	120	25.156.053 €
Human resources	81	8.357.014 €
Studies (Clinical Trials, Other Studies)	277	6.042.696 €
Contracts and provision of services	411	11.988.509 €
Donations	158	699.787 €
Mobility grants	2	30.458 €
Transfer	-	34.673 €

During 2023, funding raised in competitive calls for research projects, the recruitment of staff, infrastructures, agreements, contracts and provision of services, donations, clinical trials and observational studies generated **52.309.190 €** which will complement the resources of the institutions that take part in IDIS.



**52.309.190 €**




**AMOUNT  
2023**



Amount raised, 2023

**52.309.190 €**






Number and amount of funds raised in 2023 for projects by location



## Project funding per year



Number of projects

IP	National	International	Regional	Total
Women	31	8	11	50
Men	40	13	17	70

Project funding

IP	National	International	Regional	Total
Women	6761812 €	2.150.370 €	1.882.600 €	10.794.782 €
Men	6.152.215 €	5.124.224 €	3.084.833 €	14.361.271 €

## Number of Clinical trials and Observational studies

2023

**112**

CLINICAL  
TRIALS

**165**

OBSERVATIONAL  
STUDIES

**33**

Lead by  
women

**60**

Lead by  
women



*Observational  
studies*


*Clinical  
trials*



**STRUCTURE**

**03**

## Board of directors





## Board of directors

### President

Julio García Comesaña

### Vice-President

Antonio López-Díaz

### Chairs

Julián Álvarez Escudero

Ángel Carracedo Álvarez

Enrique Domínguez Muñoz

Antonio Fernández Campa

José Ramón González Juanatey

José Luis Labandeira García

Eloína Núñez Masid

Vicente Pérez Muñozuri

Mª Luz Couce Pico (without vote)

Isabel Lista García (without vote)

## External Scientific Committee

Ángeles Almeida Parra  
Melchor Álvarez de Mon Soto  
María del Carmen Ayuso García  
Joan Comella Carnicé  
Encarnación Guillén Navarro  
Rosario Luquin Piudo  
Antonio Vidal Puig

## non-scientific actors

Obra Social ABANCA  
Consello Social USC  
Asociación Española Contra el Cáncer - AECC  
Federación Galega de Enfermidades  
Raras e Crónicas - FEGEREC  
Financiera Maderera S.A FINSA  
Grupo FRINSA

## Internal Scientific Committee

**President**  
M<sup>a</sup> Luz Couce Pico  
**Secretary**  
José Ramón Castro Ruibal

Sofía Isabel Barbosa Sousa Gouveia  
Ángel Carracedo Álvarez  
Miriam Cebey López  
Manuel Collado Rodríguez  
Anxo Fernández Ferreiro  
José Ramón González Juanatey  
Francisco Gude Sampedro  
José Luis Labandeira García  
Isabel Lista García  
Rafael López López  
Miguel López Pérez  
Mabel Loza García  
Paula Mariño Lorenzo  
Miguel Ángel Martínez Olmos  
Federico Martinón Torres  
Laura Muinelo Romay  
Daniel Rey Aldana  
Mabel Sampedro Parada  
Ana Vega Giemmo  
Sandra Vidal Martínez

### 3. STRUCTURE



#### Quality Commission

##### **President**

Miriam Cebey López

##### **Secretary**

Iria Louzao Pernas

M<sup>a</sup> Mar Lale Candal

Isabel Lista García

Mabel Sampedro Parada

#### Training Commission

##### **President**

Manuel Collado Rodríguez

##### **Secretary**

José Ramón Castro Ruibal

Jorge Barbazán García

Sonia Eiras Penas

Ana Estany Gestal

Anxo Fernández Ferreiro

Cristina Fernández Pérez

Francisco Gude Sampedro

Ana Igea Fernández

María del Carmen Rivas Vázquez

Anxo Vidal Figueroa

#### Innovation and Transfer Commission

##### **President**

Anxo Fernández Ferreiro

##### **Secretary**

José Ramón Castro Ruibal

Luis León Mateos

Cristina Fernández Pérez

María de la Fuente Freire

Moisés Rodríguez Mañero

José Brea Floriani

Adrián Mosquera Orgeira

Mabel Sampedro Parada

#### Scientific - technical coordination

José Ramón Castro Ruibal

Yolanda Liste Martínez

Iria Louzao Pernas

## A001 ONCOLOGY

*Leaders: Rafael López López / José Manuel Castro Tubío*

<b>C010</b>	Genetics of Human Diseases	Fernando Domínguez Puente
<b>C011</b>	Pathology	José Ramón Antúnez López
<b>C025</b>	NANOBIOFAR	María José Alonso Fernández
<b>C030</b>	Traslational Medical Oncology	Rafael López López
<b>C032</b>	Molecular Imaging	Virginia Pubul Núñez
<b>C045</b>	Cell senescence, cancer and aging	Manuel Collado Rodríguez
<b>E004</b>	Molecular Oncology	José Antonio Costoya Puente
<b>E018</b>	Cell Cycle and Oncology (CiClon)	Anxo Vidal Figueroa
<b>E031</b>	Oncologic Endocrinology	Román Pérez Fernández
<b>E032</b>	Preclinical Animal Models	Laura Sánchez Piñón
<b>E033</b>	Viruses and cancer	María del Carmen Rivas Vázquez
<b>E037</b>	DNA Repair and Genome Integrity	Miguel González Blanco
<b>E040</b>	Mobile Genomes and Disease	José Manuel Castro Tubío
<b>E043</b>	Medical Physics and Biomathematics	Juan Pardo Montero
<b>E044</b>	Nano-Oncology and Translational Therapy Unit	María de la Fuente Freire
<b>E051</b>	Oral and maxillofacial medical-surgical pathology	Mario Pérez Sayáns
<b>E060</b>	Computational and genomic hematology	Adrián Mosquera Orgueira
<b>AC01</b>	Lymphoproliferative Disorders	José Luis Bello López
<b>AC06</b>	Translational ophthalmology	María José Blanco Teijeiro
<b>AC08</b>	Surgical Oncology	Manuel Bustamante Montalvo



## A002 GENETICS AND SYSTEMS BIOLOGY

*Leaders: Ángel Carracedo Álvarez / María Isabel Loza García*

<b>C005</b>	Genetics	Ángel Carracedo Álvarez
<b>C009</b>	Translational Research in Digestive Diseases	Juan Enrique Domínguez Muñoz
<b>C026</b>	BIOFARMA	María Isabel Loza García
<b>C041</b>	Cancer Genetics and Rare Diseases	Ana Paula Vega Gliemmo
<b>E012</b>	Comparative Genomics of Human Parasites	Julio Manuel Maside Rodríguez
<b>E020</b>	Psychiatric Genetics	Javier Costas Costas
<b>E021</b>	Genetics and Developmental Biology of Kidney Diseases	Miguel Ángel García González
<b>E035</b>	Genetics of Gastrointestinal Tumours	Clara Ruiz Ponte
<b>E036</b>	Stem Cells and Human Diseases	Miguel Ángel Fidalgo Pérez
<b>E047</b>	Cancer Genetics and Epidemiology Group	Manuela Gago Domínguez
<b>E054</b>	Epitranscriptomics and aging	Diana Guallar Artal
<b>E055</b>	Cancer Predisposition and Biomarkers	Ceres Fernández Rozadilla
<b>E059</b>	MitoPhenomics	Aurora Gómez Durán
<b>E061</b>	Pharmacogenomics and drug discovery	Olalla Maroñas Amigo

## A003 ENDOCRINOLOGY, NUTRITION AND METABOLISM

*Leaders: Miguel A. Martínez Olmos / Luisa Mª Seoane Camino*

<b>C001</b>	Neoplasia and Endocrine Differentiation	Clara Álvarez Villamarín
<b>C006</b>	Molecular Endocrinology	Felipe Casanueva Freijo
<b>C008</b>	Obesity and Nutrition	Carlos Diéguez González
<b>C012</b>	Metabolic Disorders	María de la Luz Couce Pico
<b>C019</b>	Thyroid and Metabolic Disorders Unit (UETeM)	David Araújo Vilar
<b>C022</b>	Paediatric Nutrition	Rosaura Leis Trabazo
<b>C029</b>	Neuroobesity	Miguel López Pérez
<b>C031</b>	Molecular Metabolism	Rubén Nogueiras Pozo
<b>C037</b>	Trace Elements, Spectroscopy and Speciation	Pilar Bermejo Barrera
<b>E023</b>	Obesidomics	María Pardo Pérez
<b>E025</b>	Cellular Endocrinology	Jesús Pérez Camiña
<b>E026</b>	Endocrine Physiopathology	Luisa María Seoane Camino
<b>E039</b>	Diabesity	Sulay Tovar Carro
<b>E041</b>	Epigenomics in Endocrinology and Nutrition	Ana Belén Crujeiras Martínez
<b>E057</b>	Translational Endocrinology	Omar Al-Massadi Iglesias
<b>AC04</b>	Paediatric Endocrinology	Lidia Castro Feijoo



## A004 NEUROSCIENCES

**Leaders:** José Luis Labandeira García / Francisco Campos Pérez

<b>C015</b>	Neurobiology of the Visual System	Francisco González García
<b>C018</b>	Experimental Neurology of Parkinson's Disease	José Luis Labandeira García
<b>C033</b>	Design, Synthesis and Medical Evaluation of Bioactive Compounds and New Materials	Antonio Mouriño Mosquera
<b>C034</b>	Physics of Polymers and Colloids	Silvia Barbosa Fernández
<b>C035</b>	R&D in Drugs Dose Forms and Delivery Systems	Ángel Concheiro Nine
<b>C036</b>	Magnetism and Nanotechnology (NanoMag)	José Rivas Rey
<b>C038</b>	Analytical Chemistry of Compounds of Alimentary, Environmental and Biological Interest	Antonia M. Carro Díaz
<b>C042</b>	Translational Stroke	Francisco Campos Pérez
<b>C043</b>	Neuroimaging and Biotechnology	Ramón Iglesias Rey
<b>C044</b>	Neuroaging	Tomás Sobrino Moreiras
<b>C046</b>	Gene Regulatory Control in Disease Laboratory	Ashwin Woodhoo
<b>E014</b>	Prion Diseases	Jesús Rodríguez Requena
<b>E019</b>	Cell Stress	Juan Bautista Zalvide Torrente
<b>E029</b>	Cognitive Neuroscience	Fernando Díaz Fernández
<b>E050</b>	Headaches and Craniofacial Pain	Rogelio Leira Muñoz
<b>E052</b>	Corneal neurodegeneration	Mª Isabel Lema Gesto
<b>E053</b>	Circadian And Glial Biology	Olga Barca Mayo
<b>AC03</b>	Critical Patient	Julián Álvarez Escudero
<b>AC22</b>	Translational Research in Neurological Diseases (ITEN)	José María Prieto González

## A005 PLATFORMS AND METHODOLOGY

**Leaders:** Francisco Gude Sampedro / Irene Zarra Ferro

<b>C002</b>	Surgery: Complications and advances	Miguel Ángel Caínzos Fernández
<b>C013</b>	Epidemiology, Public Health and Evaluation of Health Services	Adolfo Figueiras Guzmán
<b>C017</b>	Research Methodology	Francisco Gude Sampedro
<b>C021</b>	Clinical Analysis	Santiago Rodríguez-Segade Villamarín
<b>E034</b>	FarmaCHUSLab	Irene Zarra Ferro
<b>E046</b>	PARAQUASIL	José Blanco Méndez
<b>E058</b>	Oral Sciences (OSRG)	Benjamín Martín Biedma
<b>AC10</b>	Healthy ageing, fragility and chronicity. Research in Primary Care	Juan Manuel Vázquez Lago
<b>AC13</b>	Dermatology and Craniofacial Pathology (DePaCra)	Pablo Ignacio Varela Centelles
<b>AC21</b>	Pharmacological Biochemistry	Fernando J Hermida Ameijeiras
<b>AC23</b>	Nursing, Management and Care	Sandra Vidal Martínez
<b>AC24</b>	Optometry	Eva Yebra-Pimentel Vilar
<b>AC25</b>	Radiology	Miguel Souto Bayarri



## A006 CARDIOVASCULAR

*Leaders: José Ramón González Juanatey / Moisés Rodríguez Mañero*

<b>C003</b>	Hypertension	Antonio Pose Reino
<b>C016</b>	Cardiology	José Ramón González Juanatey
<b>C027</b>	Neuroendocrine Interactions in Rheumatic and Inflammatory Diseases (Neirid)	Oreste Gualillo
<b>C039</b>	Biodiscovery	Luis Miguel Botana López
<b>E001</b>	Cardiovascular Genetics	María José Brión Martínez
<b>E009</b>	Cellular and Molecular Cardiology	Francisca Lago Paz
<b>E030</b>	Platelet Proteomics	Ángel García Alonso
<b>E045</b>	Translational Cardiology	Sonia Eiras Penas
<b>E056</b>	Metabolic Homeostasis and Vascular Calcification	Ricardo Villa Bellosta
<b>AC05</b>	Pneumology	Luis Guillermo Valdés Cuadrado
<b>AC07</b>	Semergal	Sergio Cinza Sanjurjo
<b>AC19</b>	Vascular Research Group of Santiago	Diego Caicedo Valdés

## A007 INFECTOLOGY, INFLAMMATION AND VACCINES

*Leaders:* Federico Martínón Torres / Rodolfo Gómez Bahamonde


<b>C014</b>	Rheumatology	Eva Pérez Pampín
<b>C020</b>	Genetics, Vaccines, Infections & Pediatrics	Federico Martínón Torres
<b>C028</b>	Experimental and Observational Rheumatology	Antonio González Martínez-Pedrayo
<b>C040</b>	Oral Medicine and Surgery (OMEQUI)	Pedro Diz Dios
<b>C047</b>	Population Genetics in Biomedicine	Antonio Salas Ellacuriaga
<b>E013</b>	Microbiology	María Luisa Pérez del Molino Bernal
<b>E027</b>	Escherichia coli	Jorge Blanco Álvarez
<b>E038</b>	Musculoskeletal Pathology	Rodolfo Gómez Bahamonde
<b>E048</b>	Molecular and Cellular Gastroenterology	Javier Conde Aranda
<b>AC11</b>	Simulation, Life Support and Intensive Care	Antonio Rodríguez Núñez
<b>AC20</b>	Translational Research of Airway Diseases	Francisco J. González Barcala



# TRAINING & DISSEMINATION

04

## Defended PhD theses per year



**33** defended by male researchers

**57** defended by female researchers

**45** directed by, at least, one female researcher

**36** with international mention

**26** defended by women

**22** directed by, at least, one woman



## Organization of training and communication activities

12

TRAINING  
ACTIVITIES

52

SEMINARS

5

SYMPOSIA  
&  
CONFERENCES

30 "Mércores IDIS"

20 CardioCHUS Academy

2 "Experiencias emprendedoras"





7

ONE-SESSION  
SEMINARS



5

INSTITUTIONAL  
INFORMATION  
SESSION



10

OUTREACH  
ACTIVITIES





## Press, web & Social Networks

*idis\_research*



*idis\_research*



*idis\_research*



@*idis\_research*



# FOLLOWERS

### Instagram

119 posts  
Interactions:  
**>950**

### LinkedIn

78 posts

### Facebook

209 posts  
interactions:  
**>250**

### Twitter

98 posts  
impressions:  
**> 51.000**

**58.944**

Web visits

**51**

Press  
releases

[idisantiago.es](http://idisantiago.es)



# INNOVATION AND TRANSFER

# 05





## Transfer acceleration through public funding and private investment

### ITEMAS network

The Innovation Platform in Medical and Healthcare Technologies (ITEMAS) is a support structure for healthcare innovation promoted by the Carlos III Health Institute (ISCIII), whose objective is to facilitate the innovative ideas of healthcare professionals to generate value for the system, through favoring the transfer of technology, the culture of innovation and communication with the rest of society.

ITEMAS' main goal is the creation of Innovation Support Units (UAI) in hospitals and biomedical research institutes, including IDIS.


## Disseminating our research

### BioINCUBATECH

BioIncubaTech is the High Technology Incubator for the promotion of innovation and biotechnology transfer in the field of health and food technologies to micro-SMEs. BioIncubaTech belongs to "High Technology Incubators for the promotion of innovation and technology transfer to micro-SMEs" Project, aimed to modernize the regional productive fabric. These Incubators are created as traction instruments aligned with the objectives of the EU 2020 and Horizon 2020 Strategy and will promote inter-regional cooperation, as well as collaboration between public and private sector agents at international level.

IDIS collaborates since the beginning of this proposal and helped to create the project. We have 2 incubated projects.

## Intellectual property



**28**  
Female inventors

**48**  
Male inventors

**47**  
Requested  
patents

**14**  
Granted

**1**  
Licensed

**2**  
Utility  
Models

## Spin off



Personalized Medicine in Cardiology



**Active Innovations**

# **Software. Trademarks & apps**

7

TRADEMARKS


21

INTELLECTUAL  
PROPERTY



**PLATFORMS**

**06**





## PROTEOMICS

Susana Belén Bravo López

[susana.belen.bravo.lopez@sergas.es](mailto:susana.belen.bravo.lopez@sergas.es)

The Proteomics platform was created with the purpose of boosting research, providing support and offering researchers a comprehensive infrastructure in the field of proteomics managed by highly specialized staff.

It has cutting-edge equipment used to conduct complete proteome characterization studies, but also differential expression analysis studies.

## LIQUID BIOPSY UNIT

Laura Muinelo Romay

[laura.muinelo.romay@sergas.es](mailto:laura.muinelo.romay@sergas.es)

The Liquid Biopsy Analysis Unit is a laboratory specialized in the analysis of circulating tumor cells (CTCs), circulating tumor DNA (ctDNA) and other tumor elements present in different biological fluids such as blood, saliva, pleural fluid or cerebrospinal fluid, among others. others.

The unit, created in 2012, provides services to different national and international clinical and research groups for the study of liquid biopsy.

Interest in the study of tumor material present in biological fluids has increased exponentially in the last decade, mainly because it is the least invasive and most dynamic strategy for characterizing tumors.

## FLOW CYTOMETRY

Pablo Hervella Lorenzo  
[pablo.hervella.lorenzo@sergas.es](mailto:pablo.hervella.lorenzo@sergas.es)

## MAGNETIC RESONANCE IMAGING

Ramón Iglesias Rey  
[ramon.iglesias.rey@sergas.es](mailto:ramon.iglesias.rey@sergas.es)

It is a technique of cell analysis that allows to measure the characteristics of light scattering and cell fluorescence when those cells pass through a light beam. The platform's main aims are:

- » To advise users on the principles and applications of flow cytometry analysis and cell sorting.
- » To develop, optimize and perform new analytical applications demanded by the users.
- » To do cellular isolation through cell sorting.
- » To quantify different soluble cytokines using multiplex tests.

Magnetic Resonance Imaging is perhaps the most versatile neuroimaging technique that exists nowadays. The use of this platform in its different variants (anatomical, functional, spectroscopy and molecular imaging) allows for a complete, non-invasive (*in vivo*) and longitudinal monitoring over time of the process associated with neurovascular diseases and others such as plasticity, reorganization and functional recovery in animal models.



## INTEGRATED UNIT OF BIOBANKS AND BIOMODELS

Máximo Fraga;  
Rodolfo Gómez;  
Anxo Vidal

[biobanco.apa.santiago@sergas.es](mailto:biobanco.apa.santiago@sergas.es)  
[bbi3d@mpgroup.es](mailto:bbi3d@mpgroup.es)  
[cebeaga@usc.es](mailto:cebeaga@usc.es)  
[lydia.fraga.fontoira@sergas.es](mailto:lydia.fraga.fontoira@sergas.es)



With the aim of accelerating translational research by offering a comprehensive solution to the research community, currently the following Research Support Platforms dependent on SERGAS and the University of Santiago de Compostela (USC) are constituted as a unicentric integrated unit BIOBANK AND BIOMODELS:

- » Biobank CHUS – Máximo Fraga
- » Platform of Biovalidation, Biofabrication and 3D Printing (BBI-3D) – Rodolfo Gómez
- » Experimental Biomedicine Centre of the University of Santiago de Compostela (CEBEGA) – Anxo Vidal

It is a unique structure made up of these three units with the main objective of accelerating translational research. It is precisely the close relationship between the units that sustains its unique value and its potential to offer a broad portfolio of services to the research community

## MOLECULAR IMAGING UNIT

Pablo Aguiar Fernández  
[pablo.aguiar.fernandez@sergas.es](mailto:pablo.aguiar.fernandez@sergas.es)

Our mission is to bridge the gap between in vitro biomedical research and in vivo preclinical and clinical imaging, providing novel molecular imaging biomarkers and imaging probes to gain information about physiology and pathology in vivo. We offer a core facility to provide opportunities for in vivo molecular imaging based on PET, SPECT and CT technologies.

## THE ANIMAL EXPERIMENTATION UNIT

M<sup>a</sup> Luz Alonso Alonso

[maria.luz.alonso.alonso@sergas.es](mailto:maria.luz.alonso.alonso@sergas.es)

The Animal Experimentation Unit provides support in biomedical research with several animal models for IDIS research groups, in strictly controlled sanitary and environmental conditions. The Animal Experimentation Unit is accredited by the Ministry of Rural Environment of the Xunta de Galicia. It has rat and mouse housing facilities, surgery rooms and specialized qualified personnel, in accordance with current regulations. It also has an Ethics Committee on Animal Experimentation. It holds the corresponding accreditation as an Authorized Body to carry out the evaluation of projects from a scientific or educational point of view.

It is responsible for advice on issues related to animal welfare, review of internal operational processes, issuance of reports and monitoring of projects. Its objectives are to promote research, and to develop and implement biomedical training, providing professionals with the necessary resources for the development of these initiatives.



## CONFOCAL MICROSCOPY

Marta Picado Barreiro

[marta.picado.barreiro@sergas.es](mailto:marta.picado.barreiro@sergas.es)

The confocal scanning microscope is well-known for its ability to perform optical sectioning: a thin plane or section within a thick turbid medium is non-invasively imaged with high resolution and contrast. Nuclear, cellular and morphologic detail is imaged in living intact tissue without having to excise physically and prepare thin sections or cultures.

- » The services include the infrastructure and specialised staff to perform analysis as...
- » 3D imaging reconstruction.
- » Multiple labeling.
- » Colocalization.
- » In vivo fluorescence imaging.

## PHARMACOKINETICS (PK-PDRUGS)

Anxo Fernández Ferreiro

[anxordes@gmail.com](mailto:anxordes@gmail.com)

The unit (PK-PDrugs) coordinated from the Research and Innovation Unit of the Pharmacy Service of Santiago de Compostela, is committed to the most sophisticated analytical technologies focused on the determination of drugs and metabolites in the different fields of biomedical research.

## EPIGENOMICS

Ana Belén Crujeiras /  
Ángel Díaz Lagares  
[anabelencrujeiras@hotmail.com](mailto:anabelencrujeiras@hotmail.com)  
[angel.diaz.lagares@sergas.es](mailto:angel.diaz.lagares@sergas.es)

Epigenomics contributes to solving multiple biological processes related to the development of diseases and is particularly useful in the field of personalized medicine. The Epigenomics Unit, created in collaboration between the Endocrinology and Nutrition area and the Oncology area of IDIS and in consortium between FIDIS and the CIBER Physiopathology of Obesity and Nutrition (CIBERObn), aims to provide help and support to research groups and industry at a national and international level in carrying out epigenomic studies, at the level of specific genes or the epigenome.

## BIOINFORMATICS

Jorge Amigo Lechuga  
[jorge.amigo@usc.es](mailto:jorge.amigo@usc.es)

The Bioinformatics Platform is made up of a multidisciplinary team with experience in handling data obtained from omics technologies and in translational medicine. Its purpose is to provide both basic and clinical researchers with technological support and advice on the numerical analysis and processing of large volumes of data from different areas of the life sciences, applying techniques from both the fields of biology and chemistry, physics or mathematics, to obtain new knowledge.



## TRANSCRIPTOMICS

Isabel Ferreirós Vidal

*Isabel.Ferreiros.Vidal@sergas.es*

This technology allows millions of fragments to be sequenced massively and in parallel, improving the speed and accuracy of sequencing while reducing its cost.

The Illumina NextSeq 2000 Sequencing System is provided with a novel super-resolution optical system that produces high-precision imaging data with higher resolution and sensitivity than more traditional Illumina systems.

This technology also provides greater sequencing flexibility, and it is scalable to different production experimental needs and adaptable to both conventional and emerging applications.

## DIRECT DIGITAL MOLECULAR DETECTION (NANOSTRING)

Alberto Gómez Carballa

*alberto.gomez.carballa@sergas.es*

The nCounter® Assay System allows hundreds of mRNAs, miRNAs, SNVs, CNVs or proteins to be analyzed directly by direct digital molecular detection, in a single reaction in the absence of enzymes (no reverse transcription or amplification). It is a system of high sensitivity and reproducibility, with great multiplexing capacity (up to 800 genes in the same reaction). The technique not only reduces the number of necessary reactions, but also saves the amount of RNA/DNA that is used. required for the test.

## PLATFORM SP-IRIS/ EXOVIEW

María Pardo Pérez  
[beatriz.sobrino.rey@sergas.es](mailto:beatriz.sobrino.rey@sergas.es)

The ExoView platform is based on single particle interferometric reflectance imaging sensor SP-IRIS technology providing a compact multi-parameter solution for the capture and analysis of Extracellular Vesicles (EVs)/exosomes, functionalized nanoparticles and viruses. It allows capturing EVs, measuring size (nm) by means of visible light interference, and quantifying by fluorescence the number of vesicles with specific antibodies and/or on demand in small functionalized chips using very little sample (just a few  $\mu$ l) in any biological fluid (plasma, serum, urine, CSF, etc) and secretomes. It allows performing in a single analysis the size, quantity, and protein profile of both membrane and intravesicular proteins; it also allows the detection and analysis of exosomal RNAs using fluorescent probes.

## MULTIPHOTON MICROSCOPE

Pablo Hervella Lorenzo  
M<sup>a</sup> Luz Alonso Alonso  
[Maria.Luz.Alonso.Alonso@sergas.es](mailto:Maria.Luz.Alonso.Alonso@sergas.es)

The Multi-Photon Microscope is purpose-built for deep imaging not only in tissue slices and cells but also in clarified tissue, whole organs, and even whole animals. Its working spectral range makes it suitable for 2-photon microscopy applications where the lowest possible phototoxicity is sought and where it is possible to obtain high-quality images at maximum depth, such as in-vivo imaging in small animals such as mice or rats. It is also possible to obtain 2-photon imaging on marker-free samples through secondary and tertiary harmonic imaging.



## SINGLE CELL

Isabel Ferreirós Vidal  
*isabel.Ferreiros.Vidal@sergas.es*

10x Genomics technology provides a better readout of cellular complexity from different perspectives - omics at the "single cell" level: the combination of information from multiple omics layers -transcriptomics, proteomics and epigenomics- increases the power of the experiments.

## ECOCARDIO

Ricardo Lage Fernández  
*ricardo.lage@usc.es*

The objective of the unit is to provide professionals in our environment with an effective tool to assess changes in cardiac function in different preclinical models, associated with the pathophysiological process or therapeutic intervention, favoring collaborations and creating synergies between healthcare professionals and researchers.

The ECOCARDIO Cardiac Imaging Platform is made up of a multidisciplinary team with extensive experience in the analysis of cardiac function, from SERGAS, IDIS and USC. Non-invasive imaging techniques are a fundamental piece of current cardiovascular medicine, providing accurate diagnoses and providing prognostic information. In addition, they allow monitoring of different pathophysiological processes, often guiding the therapeutic intervention itself

## GENOMICS

Beatriz Sobrino Rey  
*beatriz.sobrino.rey@sergas.es*

The application of the most modern technologies of genetic or pharmaceutical analysis require, in addition to the necessary equipment, expert knowledge for the adequate interpretation of the results obtained from them.

Before starting the process it is essential to have adequate general knowledge of the field and specific knowledge of the capacities, limitations and alternatives in each particular case.

## TRANSVERSAL RESEARCH METHODOLOGY UNIT (UTAMI)

Ana Estany Gestal  
*metodologia.idis.santiago@sergas.es*

The Research Methodology Transversal Unit (UTAMI) is a support unit specialized in research methodology, biostatistics, bioethics and regulation. UTAMI is coordinated from the Research Methodology Unit of IDIS Foundation, with the aim of promoting competitive research by offering research staff a highly qualified service, aimed at promoting three fundamental aspects of research: scientific publications, research projects and doctoral theses.



**FUNDING**

**07**



HEALTH RESEARCH INSTITUTE. SANTIAGO DE COMPOSTELA



During 2023, **52.309.190 €** were raised in the following concepts: projects, human resources, transfer, donations, contracts, infrastructures, provision of services, agreements and studies.

**120**  
Projects  
**25.156.053 €**

**411**  
Contracts and  
provision of services  
**11.988.509 €**



**81**

Human resources  
8.357.014 €

**158**

Donations  
699.787 €

**277**

Studies (Clinical Trials, Other Studies)  
6.042.696 €

**2**  

Transfer  
34.673 €

**2**

Mobility  
30.458 €



**33.543.525 €**

COMPETITIVE  
FUNDING



**120**  
Projects

**25.156.053 €**

**28**

Regional projects

4.967.433 €

**71**

National projects

12.914.026 €

**21**

International projects

7.274.594 €

## Human resources

81

HUMAN RESOURCES  
8.357.014 €

AGENCY



AXENCIA  
GALEGA DE  
INNOVACIÓN



MINISTERIO  
DE CIENCIA  
E INNOVACIÓN



MINISTERIO  
DE UNIVERSIDADES





CONCEPT	NUMBER	AMOUNT
GAIN Postdoctoral Grant	10	1.158.936,94 €
GAIN Predoctoral Grant	17	1.716.146,01 €
Investigo	8	264.870,72 €
PFIS	5	449.500,00 €
iPFIS	1	89.900,00 €
Río Hortega	2	130.000,00 €
Sara Borrell	2	190.000,00 €
Miguel Servet	3	925.800,00 €
Management	1	80.700,00 €
Intensification	3	150.000,00 €
Joan Rodés	2	492.200,00 €
FPU	4	365.444,59 €
Juan de la Cierva	2	134.800,00 €
Technical Support Staff	1	43.800,00 €
Predoctoral	4	447.032,00 €
Predoctoral Grant	7	615.446,03 €
Postdoctoral Grant	2	234.941,16 €
MSCA	1	83.152,51 €
Others	6	784.344,00 €



# STRATEGIC ALLIANCES

08

# RICORS

7

**RICORS REI**  
Inflammatory Disease  
Network



**RICORS2040**  
Kidney Disease Network



**RICORS-ICTUS**  
Cerebrovascular Diseases Network



**RICORS RIAPAd**  
Network of Research in Primary Care of Addictions



**RICORS SAMID**  
Primary Care Interventions to Prevent Maternal and Child Chronic Diseases of Perinatal and Developmental Origin



**RICORS RICAPPS**  
Research Network on Chronicity, Primary Care and Prevention and Health Promotion



**RICORS TERAV**  
Advanced Therapies Network





7

## CIBER

### Biomedical Research Networking Centres

**CIBEROBN**, Physiopathology of Obesity and Nutrition

**CIBERER**, Rare Diseases

**CIBERESP**, Public Health and Epidemiology

**CIBERCV**, Cardiovascular Diseases

**CIBERONC**, Cancer

**CIBERNED**, Neurodegenerative Diseases

**CIBERES**, Respiratory Diseases

**cibер | OBN**

**cibер | ER**

**cibер | ESP**

**cibер | CV**

**cibер | ONC**

**cibер | NED**

**cibер | ES**

## PLATFORMS

3

**BIOBANKS & BIOMODELS**

**SPANISH CLINICAL RESEARCH NETWORK**

**ITEMAS**. Innovation in Medical & Health Technologies

 **PLATAFORMA ISCIPI  
BIOBANCOS Y  
BIOMODELOS**

 **SCReN**  
Spanish  
Clinical  
Research  
Network  
ISCIPI

  
**itemas isciipi**  
Plataforma de dinamización e innovación de las capacidades  
industriales del Sistema Nacional de Salud

## INTERNATIONAL NETWORK

4

**EATRIS**, European Infrastructure for Translational Medicine



**COST**, European Cooperation in Science and Technology



**EU OPENSCREEN** - European High-Capacity Screening Network



**ECRIN** - European Clinical Research Infrastructure Network



## OTHER NETWORKS

5

**RECLIP**<sup>(1)</sup>, Spanish Pediatric Clinical Trials Network.



**REGIC**, Clinical Research Management Entities Network.



Cluster Saúde de Galicia



Galicia Life Sciences Business Technological Cluster



Association of knowledge transfer



<sup>(1)</sup>National Coordination IDIS




AREAS  
09



## Publications in 2023.

Number





## Selected Publications

### ONCOLOGY

1. Abbadessa, A., Bernal, P. N., Buttitta, G., Ronca, A., D'Amora, U., Zihlmann, C., Stiefel, N., Ambrosio, L., Malda, J., Levato, R., Crecente-Campo, J., & Alonso, M. J. (2023). Biofunctionalization of 3D printed collagen with bevacizumab-loaded microparticles targeting pathological angiogenesis. *JOURNAL OF CONTROLLED RELEASE*, 360, 747–758. <https://doi.org/10.1016/j.jconrel.2023.07.017>
2. Bruzos, A. L., Santamarina, M., Garcia-Souto, D., Diaz, S., Rocha, S., Zamora, J., Lee, Y., Vina-Feas, A., Quail, M. A., Otero, I., Pequeno-Valtierra, A., Temes, J., Rodriguez-Castro, J., Aramburu, L., Vidal-Capon, A., Villanueva, A., Costas, D., Rodriguez, R., Prieto, T., ... Tubio, J. M. C. (2023). Somatic evolution of marine transmissible leukemias in the common cockle, *Cerastoderma edule*. *NATURE CANCER*, 4(11). <https://doi.org/10.1038/s43018-023-00641-9>
3. Diez-Villares, S., Garcia-Varela, L., Groba-de Antas, S., Ramon Caeiro, J., Carpintero-Fernandez, P., Mayan, M. D., Aguiar, P., & de la Fuente, M. (2023). Quantitative PET tracking of intra-articularly administered <sup>89</sup>Zr-peptide-decorated nanoemulsions. *JOURNAL OF CONTROLLED RELEASE*, 356, 702–713. <https://doi.org/10.1016/j.jconrel.2023.03.025>
4. Rapado-Gonzalez, O., Rodriguez-Ces, A. M., Lopez-Lopez, R., & Suarez-Cunqueiro, M. M. (2023). Liquid biopsies based on cell-free DNA as a potential biomarker in head and neck cancer. *JAPANESE DENTAL SCIENCE REVIEW*, 59, 289–302. <https://doi.org/10.1016/j.jdsr.2023.08.004>
5. Villar-Alvarez, E., Golan-Cancela, I., Pardo, A., Velasco, B., Fernandez-Vega, J., Cambon, A., Al-Modlej, A., Topete, A., Barbosa, S., Costoya, J. A., & Taboada, P. (2023). Inhibiting HER3 Hyperphosphorylation in HER2-Overexpressing Breast Cancer through Multimodal Therapy with Branched Gold Nanoshells. *SMALL*, 19(50). <https://doi.org/10.1002/smll.202303934>

## GENETICS AND SYSTEMS BIOLOGY

1. Bonjoch, L., Fernandez-Rozadilla, C., Alvarez-Barona, M., Lopez-Novo, A., Herrera-Pariente, C., Amigo, J., Bujanda, L., Remedios, D., Dacal, A., Cubilla, J., Balaguer, F., Fernández-Bañares, F., Carracedo, A., Jover, R., Castellvi-Bel, S., & Ruiz-Ponte, C. (2023). *BMPR2* as a Novel Predisposition Gene for Hereditary Colorectal Polyposis. *GASTROENTEROLOGY*, 165(1). <https://doi.org/10.1053/j.gastro.2023.03.006>
2. Lariño-Noia, J., Fernández-Castroagudín, J., de la Iglesia-García, D., Lázare, H., Nieto, L., Porto, S., Vallejo-Senra, N., Molina, E., San Bruno, A., Martínez-Seara, X., Iglesias-García, J., García-Acuña, S., & Domínguez-Muñoz, J. E. (2023). Quality of Tissue Samples Obtained by Endoscopic Ultrasound-Guided Liver Biopsy: A Randomized, Controlled Clinical Trial. *AMERICAN JOURNAL OF GASTROENTEROLOGY*, 118(10), 1821–1828. <https://doi.org/10.14309/ajg.0000000000002375>
3. Castro-Santos, P., Rojas-Martinez, A., Riancho, J. A., Lapunzina, P., Flores, C., Carracedo, A., Díaz-Peña, R., & Grp, S. C. (2023). *HLA-A11:01* and *HLA-C04:01* are associated with severe COVID-19. *HLA*, 102(6), 731–739. <https://doi.org/10.1111/tan.15160>
4. Al-Soufi, L., & Costas, J. (2023). Genetic susceptibility for schizophrenia after adjustment by genetic susceptibility for smoking: implications in identification of risk genes and genetic correlation with related traits. *PSYCHOLOGICAL MEDICINE*, 53(14), 6806–6816. <https://doi.org/10.1017/S0033291723000326>
5. Dominguez-Alonso, S., Carracedo, A., & Rodriguez-Fontenla, C. (2023). eQTL colocalization analysis highlights novel susceptibility genes in Autism Spectrum Disorders (ASD). *TRANSLATIONAL PSYCHIATRY*, 13(1). <https://doi.org/10.1038/s41398-023-02621-0>



## ENDOCRINOLOGY, NUTRITION AND METABOLISM

1. Gonzalez-Rellan, M. J., Fernández, U., Parracho, T., Novoa, E., Fondevila, M. F., Lima, N. D., Ramos, L., Rodríguez, A., Serrano-Maciá, M., Perez-Mejías, G., Chantada-Vazquez, P., Riobello, C., Veyrat-Durebex, C., Tovar, S., Coppari, R., Woodhoo, A., Schwaninger, M., Prevot, V., Delgado, T. C., ... Nogueiras, R. (2023). Neddylation of phosphoenolpyruvate carboxykinase 1 controls glucose metabolism. *CELL METABOLISM*, 35(9), 1630-1645. <https://doi.org/10.1016/j.cmet.2023.07.003>
2. Gonzalez-Rellan, M. J., Novoa, E., Da Silva Lima, N., Rodriguez, A., Veyrat-Durebex, C., Seoane, S., Porteiro, B., Fondevila, M. F., Fernandez, U., Varela-Rey, M., Senra, A., Iglesias, C., Escudero, A., Fidalgo, M., Guallar, D., Perez-Fernandez, R., Prevot, V., Schwaninger, M., López, M., ... Nogueiras, R. (2023). Hepatic p63 regulates glucose metabolism by repressing SIRT1. *Gut*, 72(3), 472–483. <https://doi.org/10.1136/gutjnl-2021-326620>
3. González-Vila, A., Luengo-Mateos, M., Silveira-Loureiro, M., Garrido-Gil, P., Ohinska, N., González-Domínguez, M., Labandeira-García, J. L., García-Cáceres, C., López, M., & Barca-Mayo, O. (2023). Astrocytic insulin receptor controls circadian behavior via dopamine signaling in a sexually dimorphic manner. *NATURE COMMUNICATIONS*, 14(1). <https://doi.org/10.1038/s41467-023-44039-8>
4. Milbank, E., Dragano, N., Vidal-Gómez, X., Rivas-Limeres, V., Garrido-Gil, P., Wertheimer, M., Recoquillon, S., Pata, M. P., Labandeira-García, J. L., Diéguez, C., Nogueiras, R., Martínez, M. C., Andriantsitohaina, R., & López, M. (2023). Small extracellular vesicle targeting of hypothalamic AMPK $\alpha$ 1 promotes weight loss in leptin receptor deficient mice. *METABOLISM-CLINICAL AND EXPERIMENTAL*, 139. <https://doi.org/10.1016/j.metabol.2022.155350>
5. Gonzalez-Rellan, M. J., Parracho, T., Heras, V., Rodriguez, A., Fondevila, M. F., Novoa, E., Lima, N., Varela-Rey, M., Senra, A., Chantada-Vazquez, M. D. P., Ameneiro, C., Bernardo, G., Fernández-Ramos, D., Lopitz-Otsoa, F., Bilbao, J., Guallar, D., Fidalgo, M., Bravo, S., Dieguez, C., ... Nogueiras, R. (2023). Hepatocyte-specific O-GlcNAc transferase downregulation ameliorates nonalcoholic steatohepatitis by improving mitochondrial function. *MOLECULAR METABOLISM*, 75. <https://doi.org/10.1016/j.molmet.2023.101776c>

## NEUROSCIENCES

1. González-Vila, A., Luengo-Mateos, M., Silveira-Loureiro, M., Garrido-Gil, P., Ohinska, N., González-Domínguez, M., Labandeira-García, J. L., García-Cáceres, C., López, M., & Barca-Mayo, O. (2023). Astrocytic insulin receptor controls circadian behavior via dopamine signaling in a sexually dimorphic manner. *NATURE COMMUNICATIONS*, 14(1). <https://doi.org/10.1038/s41467-023-44039-8>
2. Pedrosa, M. A., Labandeira, C. M., Valenzuela, R., Quijano, A., Sanchez-Andrade, M., Suarez-Quintanilla, J. A., Lanciego, J. L., Labandeira-Garcia, J. L., & Rodriguez-Perez, A. I. (2023). AT1 receptor autoantibodies mediate effects of metabolic syndrome on dopaminergic vulnerability. *BRAIN BEHAVIOR AND IMMUNITY*, 108, 255–268. <https://doi.org/10.1016/j.bbi.2022.12.009>
3. Surpi, A., Murgia, M., López-Amoedo, S., González-Gómez, M. A., Piñeiro, Y., Rivas, J., Perugini, V., Santin, M., Sobrino, T., Greco, P., Campos, F., & Dediú, V. A. (2023). Magnetic separation and concentration of A $\beta$  1-42 molecules dispersed at the threshold concentration for Alzheimer's disease diagnosis in clinically-relevant volumes of sample. *JOURNAL OF NANOBIOTECHNOLOGY*, 21(1). <https://doi.org/10.1186/s12951-023-02095-8>
4. Pita-Vilar, M., Concheiro, A., Alvarez-Lorenzo, C., & Diaz-Gomez, L. (2023). Recent advances in 3D printed cellulose-based wound dressings: A review on in vitro and in vivo achievements. *CARBOHYDRATE POLYMERS*, 321. <https://doi.org/10.1016/j.carbpol.2023.121298>
5. Custodio-Mendoza, J. A., Ramos, A., Lorenzo, R. A., & Carro, A. M. (2023). Ultrasound-assisted enzymatic indirect determination of total 3-mono-chloropropane-1,2-diol esters in canned fish oil fraction. *FOOD CHEMISTRY*, 403. <https://doi.org/10.1016/j.foodchem.2022.134423>



## PLATFORMS AND METHODOLOGY

1. Blanco-Fernández, G., Blanco-Fernandez, B., Fernández-Ferreiro, A., & Otero-Espinar, F. J. (2023). Lipidic lyotropic liquid crystals: Insights on biomedical applications. *ADVANCES IN COLLOID AND INTERFACE SCIENCE*, 313. <https://doi.org/10.1016/j.cis.2023.102867>
2. Regueira-Iglesias, A., Vázquez-González, L., Balsa-Castro, C., Vila-Blanco, N., Blanco-Pintos, T., Tamames, J., Carreira, M. J., & Tomás, I. (2023). In silico evaluation and selection of the best 16S rRNA gene primers for use in next-generation sequencing to detect oral bacteria and archaea. *MICROBIOME*, 11(1). <https://doi.org/10.1186/s40168-023-01481-6>
3. Sáenz-Aldea, M., Salgado-Barreira, A., Trunk, M. T., Piñeiro-Lamas, M., Herdeiro, M. T., Portela-Romero, M., Saez, M., & Figueiras, A. (2023). Colchicine and risk of hospitalization due to COVID-19: A population-based study. *JOURNAL OF MEDICAL VIROLOGY*, 95(2). <https://doi.org/10.1002/jmv.28496>
4. Visos-Varela, I., Zapata-Cachafeiro, M., Pintos-Rodríguez, S., Bugarín-González, R., González-Barcala, F. J., Herdeiro, M. T., Piñeiro-Lamas, M., Figueiras, A., & Salgado-Barreira, A. (2023). Outpatient atorvastatin use and severe COVID-19 outcomes: A population-based study. *JOURNAL OF MEDICAL VIROLOGY*, 95(7). <https://doi.org/10.1002/jmv.28971>
5. Bendicho-Lavilla, C., Seoane-Viaño, I., Santos-Rosales, V., Díaz-Tomé, V., Carracedo-Pérez, M., Luzardo-Alvarez, A. M., García-González, C. A., & Otero-Espinar, F. J. (2023). Intravitreal implants manufactured by supercritical foaming for treating retinal diseases. *JOURNAL OF CONTROLLED RELEASE*, 362, 342–355. <https://doi.org/10.1016/j.jconrel.2023.08.047>

## CARDIOVASCULAR

1. Aragón-Herrera, A., Moraña-Fernández, S., Otero-Santiago, M., Anido-Varela, L., Campos-Toimil, M., García-Seara, J., Román, A., Seijas, J., García-Caballero, L., Rodríguez, J., Tarazón, E., Roselló-Lléí, E., Portolés, M., Lage, R., Gualillo, O., González-Juanatey, J. R., Feijóo-Bandín, S., & Lago, F. (2023). The lipidomic and inflammatory profiles of visceral and subcutaneous adipose tissues are distinctly regulated by the SGLT2 inhibitor empagliflozin in Zucker diabetic fatty rats. *BIOMEDICINE & PHARMACOTHERAPY*, 161. <https://doi.org/10.1016/j.biopha.2023.114535>
2. Rocha, J. C., Ahring, K. K., Bausell, H., Bilder, D. A., Harding, C. O., Inwood, A., Longo, N., Muntau, A. C., Pessoa, A. L. S., Rohr, F., Sivri, S., & Hermida, A. (2023). Expert Consensus on the Long-Term Effectiveness of Medical Nutrition Therapy and Its Impact on the Outcomes of Adults with Phenylketonuria. *NUTRIENTS*, 15(18). <https://doi.org/10.3390/nu15183940>
3. González-Rodríguez, M., Edjoudi, D. A., Cordero-Barreal, A., Farrag, M., Varela-García, M., Torrijos-Pulpón, C., Ruiz-Fernández, C., Capuozzo, M., Ottaiano, A., Lago, F., Pino, J., Farrag, Y., & Gualillo, O. (2023). Oleocanthal, an Antioxidant Phenolic Compound in Extra Virgin Olive Oil (EVOO): A Comprehensive Systematic Review of Its Potential in Inflammation and Cancer. *ANTIOXIDANTS*, 12(12). <https://doi.org/10.3390/antiox12122112>
4. Arias, F. G. R., Otero, M. I. G., Cruz, N. B., Vega, D. G., Ferrero, T. G., Minguito-Carazo, C., Monzonís, A. M., Juanatey, J. R. G., & Rodríguez-Mañero, M. (2023). Effects of guideline-directed medical therapy in patients with left bundle branch block-induced cardiomyopathy. *REVISTA ESPANOLA DE CARDIOLOGIA*, 76(4), 238–244. <https://doi.org/10.1016/j.rec.2022.07.005>
5. López-Dequidt, I., Martínez-Monzonis, A., Peña-Gil, C., González-Maestro, A., González-Salvado, V., Rodríguez-Castro, E., Santamaría-Cadavid, M., Arias-Rivas, S., Rodríguez-Yáñez, M., González, J. M. P., & González-Juanatey, J. (2023). Results of a focused cardiac ultrasound program conducted by neurologists within a stroke care network with cardiac imaging units. *REVISTA ESPANOLA DE CARDIOLOGIA*, 76(2), 103–111. <https://doi.org/10.1016/j.recesp.2022.06.002>



## INFECTOLOGY, INFLAMMATION AND VACCINES


1. Martinón-Torres, F., Mirás-Carballal, S., & Durán-Parrondo, C. (2023). Early lessons from the implementation of universal respiratory syncytial virus prophylaxis in infants with long-acting monoclonal antibodies, Galicia, Spain, September and October 2023. *EUROSURVEILLANCE*, 28(49). <https://doi.org/10.2807/1560-7917.ES.2023.28.49.2300606>
2. Liñares, A., Dopico, J., Magrin, G., & Blanco, J. (2023). Critical review on bone grafting during immediate implant placement. *PERIODONTOLOGY 2000*, 93(1), 309–326. <https://doi.org/10.1111/prd.12516>
3. Vázquez-Mera, S., Martelo-Vidal, L., Miguéns-Suárez, P., Saavedra-Nieves, P., Arias, P., González-Fernández, C., Mosteiro-Añón, M., Corbacho-Abelaira, M. D., Blanco-Aparicio, M., Méndez-Brea, P., Salgado, F. J., Nieto-Fontarigo, J. J., & González-Barcala, F. J. (2023). Serum exosome inflamma-miRs are surrogate biomarkers for asthma phenotype and severity. *ALLERGY*, 78(1), 141–155. <https://doi.org/10.1111/all.15480>
4. Gómez-Carballa, A., Albericio, G., Montoto-Louzao, J., Pérez, P., Astorgano, D., Rivero-Calle, I., Martinón-Torres, F., Esteban, M., Salas, A., & García-Arriaza, J. (2023). Lung transcriptomics of K18-hACE2 mice highlights mechanisms and genes involved in the MVA-S vaccine-mediated immune response and protection against SARS-CoV-2 infection. *ANTIVIRAL RESEARCH*, 220. <https://doi.org/10.1016/j.antiviral.2023.105760>
5. Franco-Trepat, E., Alonso-Pérez, A., Guillán-Fresco, M., López-Fagúndez, M., Pazos-Pérez, A., Crespo-Golmar, A., Bravo, S. B., López-López, V., Jorge-Mora, A., Cerón-Carrasco, J. P., Iglesias, A. L., & Gómez, R. (2023).  $\beta$  Boswellic Acid Blocks Articular Innate Immune Responses: An In Silico and In Vitro Approach to Traditional Medicine. *ANTIOXIDANTS*, 12(2). <https://doi.org/10.3390/antiox12020371>

## CLINICAL PRACTICE GUIDELINES

1. Botana Rial M, Pérez Pallarés J, Cases Viedma E, López González FJ, Porcel JM, Rodríguez M, Romero Romero B, Valdés Cuadrado L, Villena Garrido V, Cordovilla Pérez R. (2023). Diagnosis and Treatment of Pleural Effusion. Recommendations of the Spanish Society of Pulmonology and Thoracic Surgery. Update 2022. *Arch Bronconeumol.* 2023 Jan;59(1):27-35. doi: 10.1016/j.arbres.2022.09.017.
2. Crespo J, Cabezas J, Aguilera A, Berenguer M, Buti M, Forns X, García F, García-Samaniego J, Hernández-Guerra M, Jorquera F, Lazarus JV, Lens S, Martró E, Pineda JA, Prieto M, Rodríguez-Frías F, Rodríguez M, Serra MÁ, Turnes J, Domínguez-Hernández R, Casado MÁ, Calleja JL. (2023). Recommendations for the integral diagnosis of chronic viral hepatitis in a single analytical extraction. *Gastroenterol Hepatol.* 2023 Feb;46(2):150-162. doi: 10.1016/j.gastrohep.2022.09.009. Epub 2022 Oct 17.
3. Sánchez-Ocaña R, Foruny Olcina JR, Vila Costas J, Gallego Rojo F, Jiménez Pérez J, Domínguez-Muñoz E, González Huix F, Pons Beltrán V, Gornals Soler J, Sánchez Hernández E, Gómez Oliva C, Dolz Abadía C, Aparicio Tormo JR. (2023). *Gastroenterol Hepatol.* 2023 Jan;46(1):69-79. doi: 10.1016/j.gastrohep.2022.08.012.



$$\sum f_i$$



fi

*Platforms and Methodology**Cardiovascular**Infectology, Inflammation and Vaccines*

# 09. AREAS



100




Theses



Patents



## Projects



Oncology

Genetics and Systems Biology

Endocrinology, Nutrition and Metabolism



Neurosciences

Platforms and Methodology

Cardiovascular

Infectiology, Inflammation and Vaccines

## Contracts & Services





# BALANCE DE SITUACIÓN Y CUENTA DE RESULTADOS

10



# 10.

## BALANCE DE SITUACIÓN Y CUENTA DE RESULTADOS

ACTIVO	NOTAS	31/12/2023	31/12/2022
<b>A) ACTIVO NO CORRIENTE</b>		<b>14.246.581,18 €</b>	<b>13.367.871,13 €</b>
I. Inmovilizado intangible	5	<b>8.380,77 €</b>	<b>27.088,39 €</b>
5. Aplicaciones informáticas		8.380,77 €	27.088,39 €
III. Inmovilizado material	6	<b>2.678.098,07 €</b>	<b>2.294.678,40 €</b>
1. Terrenos y construcciones		1.667.235,52 €	1.375.201,14 €
2. Instalaciones técnicas y otro inmovilizado material		1.010.862,55 €	919.477,26 €
VI. Inversiones financieras a largo plazo	8.1	<b>11.560.102,34 €</b>	<b>11.046.104,34 €</b>
1. Instrumentos de Patrimonio		11.559.202,34 €	11.045.204,34 €
5. Otros activos financieros		900,00 €	900,00 €
<b>B) ACTIVO CORRIENTE</b>		<b>43.415.825,19 €</b>	<b>39.001.140,43 €</b>
I. Usuarios y otros deudores de la actividad propia	9	<b>3.810.921,18 €</b>	<b>1.318.707,33 €</b>
II. Existencias		<b>0,00 €</b>	<b>2.729,70 €</b>
6. Anticipos a proveedores		0,00 €	2.729,70 €
III. Deudores comerciales y otras cuentas a cobrar	9	<b>12.312.032,31 €</b>	<b>9.541.913,50 €</b>
3. Deudores varios		0,00 €	600,00 €
6. Otros créditos con las Administraciones Públicas		12.312.032,31 €	9.541.313,50 €
V. Inversiones financieras a corto plazo		<b>21.416.124,93 €</b>	<b>0,00 €</b>
3. Valores representativos de deuda		416.124,93 €	0,00 €
5. Otros activos financieros		21.000.000,00 €	0,00 €
VI. Periodificaciones a corto plazo		<b>40.162,58 €</b>	<b>22.534,12 €</b>
VII. Efectivo y otros activos líquidos equivalentes	11	<b>5.836.584,19 €</b>	<b>28.115.255,78 €</b>
1. Tesorería		5.836.584,19 €	28.115.255,78 €
<b>TOTAL ACTIVO (A + B)</b>		<b>57.662.406,37 €</b>	<b>52.369.011,56 €</b>

<b>PATRIMONIO NETO Y PASIVO</b>			<b>31/12/2023</b>	<b>31/12/2022</b>
<b>A)</b>	<b>PATRIMONIO NETO</b>		<b>7.919.565,15 €</b>	<b>7.127.896,22 €</b>
A-1)	<b>Fondos propios</b>	12	<b>6.471.355,63 €</b>	<b>6.339.955,66 €</b>
I.	Dotación fundacional / Fondo social		<b>153.952,45 €</b>	<b>153.952,45 €</b>
	Dotación fundacional / Fondo social		153.952,45 €	153.952,45 €
II.	<b>Reservas</b>		<b>6.186.003,21 €</b>	<b>6.282.893,75 €</b>
	Otras reservas		6.186.003,21 €	6.282.893,75 €
IV.	<b>Excedente del ejercicio</b>	3	<b>131.399,97 €</b>	<b>-96.890,54 €</b>
A-2)	<b>Ajustes por cambio de valor</b>		<b>-371.169,44 €</b>	<b>-963.287,68 €</b>
	Activos financieros disponibles para la venta		-371.169,44 €	-963.287,68 €
A-3)	<b>Subvenciones, donaciones y legados recibidos</b>	17	<b>1.819.378,96 €</b>	<b>1.751.228,24 €</b>
I.	<b>Subvenciones</b>		175.350,89 €	195.451,44 €
II.	<b>Donaciones y legados</b>		1.644.028,07 €	1.555.776,80 €
<b>B)</b>	<b>PASIVO NO CORRIENTE</b>		<b>302.249,62 €</b>	<b>547.086,30 €</b>
I.	<b>Provisiones a largo plazo</b>	15	<b>302.249,62 €</b>	<b>547.086,30 €</b>
1.	Obligaciones por prestaciones a largo plazo al personal		302.249,62 €	547.086,30 €
<b>C)</b>	<b>PASIVO CORRIENTE</b>		<b>49.440.591,60 €</b>	<b>44.694.029,04 €</b>
I.	<b>Provisiones a corto plazo</b>	15	<b>17.548.893,67 €</b>	<b>13.983.665,35 €</b>
II.	<b>Deudas a corto plazo</b>	8.2	<b>30.777.831,89 €</b>	<b>26.589.868,08 €</b>
5.	Otras deudas a corto plazo		30.777.831,89 €	26.589.868,08 €
V.	<b>Acreedores comerciales y otras cuentas a pagar</b>	10	<b>1.113.866,04 €</b>	<b>4.120.495,61 €</b>
1.	Proveedores		118.027,87 €	25.944,36 €
3.	Acreedores varios		89.039,93 €	69.985,52 €
4.	Personal (remuneraciones pendientes de pago)		220.895,59 €	226.181,70 €
6.	Otras deudas con las Administraciones Públicas		685.902,65 €	3.798.384,03 €
<b>TOTAL PATRIMONIO NETO Y PASIVO (A + B + C)</b>			<b>57.662.406,37 €</b>	<b>52.369.011,56 €</b>

## 10.

## BALANCE DE SITUACIÓN Y CUENTA DE RESULTADOS

A)	Excedente del ejercicio	NOTAS	31/12/23	31/12/22
1.	<b>Ingresos de la actividad propia</b>		<b>27.889.801,42 €</b>	<b>21.450.420,34 €</b>
	b) Aportaciones de usuarios		8.895.287,17 €	7.336.241,60 €
	c) Ingresos de promociones, patrocinadores y colaboraciones	14.d	5.313.950,16 €	3.446.972,26 €
	d) Subvenciones imputados al excedente del ejercicio	17	12.899.560,06 €	10.011.761,36 €
	e) Donaciones y legados imputados al excedente del ejercicio	17	781.004,03 €	655.445,12 €
2.	<b>Gastos por ayudas y otros</b>	14.a	<b>-1.024.929,19 €</b>	<b>-974.386,97 €</b>
	a) Ayudas monetarias		-1.022.459,94 €	-970.507,90 €
	b) Reintegro de subvenciones, donaciones y legados		-2.469,25 €	-3.879,07 €
5.	<b>Aprovisionamientos</b>	14.b	<b>-4.480.642,47 €</b>	<b>-3.547.648,80 €</b>
7.	<b>Gastos de personal</b>		<b>-11.668.606,51 €</b>	<b>-10.079.560,68 €</b>
	a) Sueldos, salarios y asimilados		-9.077.645,69 €	-8.182.208,86 €
	b) Cargas sociales	14.c	-2.835.797,50 €	-2.408.643,48 €
	c) Provisiones		244.836,68 €	511.291,66 €
8.	<b>Otros gastos de la actividad</b>		<b>-9.882.121,98 €</b>	<b>-6.226.305,20 €</b>
	a) Servicios exteriores		-6.337.931,68 €	-3.966.036,60 €
	b) Tributos		-4.688,97 €	-9.572,89 €
	c) Pérdidas, deterioro y variación de provisiones por operaciones comerciales		-3.539.501,33 €	-2.250.695,71 €
9.	<b>Amortización del inmovilizado</b>	5	<b>-2.428.070,63 €</b>	<b>-998.267,89 €</b>
10.	<b>Subvenciones, donaciones y legados de capital traspasados al excedente del ejercicio</b>		<b>1.319.518,79 €</b>	<b>280.298,45 €</b>
	a) Subvenciones de capital traspasadas al excedente del ejercicio		1.270.168,46 €	189.263,67 €
	b) Donaciones y legados de capital traspasados al excedente del ejercicio		49.350,33 €	91.034,78 €
13.	<b>Resultado excepcional</b>		<b>3.378,75 €</b>	<b>0,00 €</b>
	a)Ingresos excepcionales		3.378,75 €	0,00 €
A.1)	<b>EXCEDENTE DE LA ACTIVIDAD (1+2+3+4+5+6+7+8+9+10+11+12+13)</b>		<b>-271.671,82 €</b>	<b>-95.450,75 €</b>
14.	<b>Ingresos financieros</b>	8	<b>447.493,83 €</b>	<b>886,32 €</b>
	b) De valores negociables y otros instrumentos financieros		447.493,83 €	886,32 €
	b2)De terceros		447.493,83 €	886,32 €
15.	<b>Gastos financieros</b>	8	<b>-22.414,14 €</b>	<b>-2.565,92 €</b>
	b) Por deudas con terceros		-22.414,14 €	-2.565,92 €
16.	<b>Variación de valor razonable en instrumentos financieros</b>		<b>-21.779,46 €</b>	<b>0,00 €</b>
	b) Imputación al excedente del ejercicio por activos financieros disponibles para la venta		-21.779,46 €	0,00 €
17.	<b>Diferencias de Cambio</b>		<b>-228,44 €</b>	<b>239,81 €</b>
A.2)	<b>EXCEDENTE DE LAS OPERACIONES FINANCIERAS (13+14+15+16+17)</b>		<b>403.071,79 €</b>	<b>-1.439,79 €</b>
A.3)	<b>EXCEDENTE ANTES DE IMPUESTOS (A.1+A.2)</b>		<b>131.399,97 €</b>	<b>-96.890,54 €</b>
A.4)	<b>Variación de patrimonio neto reconocida en el excedente del ejercicio (A.3 + 18)</b>		<b>131.399,97 €</b>	<b>-96.890,54 €</b>

<b>(B) Ingresos y gastos imputados directamente al patrimonio neto**</b>			
1. Activos financieros disponibles para la venta.	570.338,78 €	-1.333.219,78 €	
3. Subvenciones recibidas.	14.149.627,97 €	10.180.924,48 €	
4. Donaciones y legados recibidos.	918.605,63 €	965.956,83 €	
<b>B.1) Variación de patrimonio por ingresos y gastos reconocidos directamente en patrimonio neto (1+2+3+4+5+6)</b>	<b>15.638.572,38 €</b>	<b>9.813.661,53 €</b>	
<b>C) Reclasificaciones al excedente del ejercicio.</b>			
1. Activos financieros disponibles para la venta.	21.779,46 €	0,00 €	
3. Subvenciones recibidas.	-14.169.728,52 €	-10.201.025,03 €	
4. Donaciones y legados recibidos.	-830.354,36 €	-746.479,90 €	
<b>Variación de patrimonio neto por reclasificaciones al excedente del ejercicio (1+2+3+4+5)</b>	<b>-14.978.303,42 €</b>	<b>-10.947.504,93 €</b>	
<b>D) Variaciones de patrimonio neto por ingresos y gastos imputados directamente al patrimonio neto (B.1 + C.1)**</b>	<b>660.268,96 €</b>	<b>-1.133.843,40 €</b>	
<b>F) Ajustes por errores</b>	<b>139.121,58 €</b>	<b>-221.048,00 €</b>	
<b>I) RESULTADO TOTAL, VARIACIÓN DEL PATRIMONIO NETO EN EL EJERCICIO (A.4+D+E+F+G+H)</b>	<b>930.790,51 €</b>	<b>-1.212.312,77 €</b>	





**HEALTH RESEARCH INSTITUTE. SANTIAGO DE COMPOSTELA**



# INSTITUTO DE INVESTIGACIÓN SANITARIA SANTIAGO DE COMPOSTELA



XUNTA DE GALICIA  
CONSELLERÍA DE SANIDADE

**idis**

**USC**  
UNIVERSIDADE  
DE SANTIAGO  
DE COMPOSTELA

**hir**

HR EXCELLENCE IN RESEARCH